Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Liposomes: a nanoscale drug carrying system to prevent indomethacin passage to the fetus in a pregnant mouse model

Liposomes: a nanoscale drug carrying system to prevent indomethacin passage to the fetus in a... Prematurity is a leading cause of perinatal morbidity and mortality affecting 12% of approximately 4 million deliveries in the United States annually. 1 Very few drugs have been proven to be effective in the treatment of preterm labor to improve neonatal outcomes. 2-4 Unfortunately, tocolytic modalities that have shown to be effective are often limited in their use due to associated toxicities to the fetus.</P>Indomethacin (IND) is a commonly used tocolytic agent from the nonsteroidal antiinflammatory drugs family. The role of prostaglandins in the initiation of labor is well documented. 5 IND is a nonselective cyclooxygenase, or prostaglandin-endoperoxide synthetase, inhibitor that suppresses the production of prostaglandins in the uterus and other locations, thus, inhibiting preterm labor. 6,7 Numerous randomized controlled trials comparing IND to either placebo or other tocolytic agents have shown a significant delay in delivery of up to 48 hours in 90-94% and up to 7 days in 75% of cases. 8-18 The clinical use of IND has been tempered by concerns over fetal and neonatal complications related to its ability to cross the placenta. 7,17-19 Fetal exposure to IND is associated with the development of antenatal closure of the ductus arteriosus, 20-22 antenatal oligohydramnios, 23,24 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Obstetrics and Gynecology Wolters Kluwer Health

Liposomes: a nanoscale drug carrying system to prevent indomethacin passage to the fetus in a pregnant mouse model

Loading next page...
 
/lp/wolters-kluwer-health/liposomes-a-nanoscale-drug-carrying-system-to-prevent-indomethacin-Tw5DNKqS8v

References (69)

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2015 Elsevier Inc.
ISSN
0002-9378
DOI
10.1016/j.ajog.2015.02.006
pmid
25683966
Publisher site
See Article on Publisher Site

Abstract

Prematurity is a leading cause of perinatal morbidity and mortality affecting 12% of approximately 4 million deliveries in the United States annually. 1 Very few drugs have been proven to be effective in the treatment of preterm labor to improve neonatal outcomes. 2-4 Unfortunately, tocolytic modalities that have shown to be effective are often limited in their use due to associated toxicities to the fetus.</P>Indomethacin (IND) is a commonly used tocolytic agent from the nonsteroidal antiinflammatory drugs family. The role of prostaglandins in the initiation of labor is well documented. 5 IND is a nonselective cyclooxygenase, or prostaglandin-endoperoxide synthetase, inhibitor that suppresses the production of prostaglandins in the uterus and other locations, thus, inhibiting preterm labor. 6,7 Numerous randomized controlled trials comparing IND to either placebo or other tocolytic agents have shown a significant delay in delivery of up to 48 hours in 90-94% and up to 7 days in 75% of cases. 8-18 The clinical use of IND has been tempered by concerns over fetal and neonatal complications related to its ability to cross the placenta. 7,17-19 Fetal exposure to IND is associated with the development of antenatal closure of the ductus arteriosus, 20-22 antenatal oligohydramnios, 23,24

Journal

American Journal of Obstetrics and GynecologyWolters Kluwer Health

Published: Apr 1, 2015

There are no references for this article.